MX2019005435A - Composicion farmaceutica, metodos para tratamiento y sus usos. - Google Patents

Composicion farmaceutica, metodos para tratamiento y sus usos.

Info

Publication number
MX2019005435A
MX2019005435A MX2019005435A MX2019005435A MX2019005435A MX 2019005435 A MX2019005435 A MX 2019005435A MX 2019005435 A MX2019005435 A MX 2019005435A MX 2019005435 A MX2019005435 A MX 2019005435A MX 2019005435 A MX2019005435 A MX 2019005435A
Authority
MX
Mexico
Prior art keywords
treating
methods
pharmaceutical composition
chronic kidney
kidney disease
Prior art date
Application number
MX2019005435A
Other languages
English (en)
Inventor
Von Eynatten Maximilian
Christian Broedl Uli
Woerle Hans-Juergen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2019005435A publication Critical patent/MX2019005435A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Abstract

La presente invención se refiere a métodos para tratar o prevenir la enfermedad renal crónica y la enfermedad cardiovascular en pacientes con enfermedad renal crónica, que comprenden administrar empagliflozina al paciente.
MX2019005435A 2016-11-10 2017-11-08 Composicion farmaceutica, metodos para tratamiento y sus usos. MX2019005435A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662420062P 2016-11-10 2016-11-10
US201762514249P 2017-06-02 2017-06-02
PCT/EP2017/078577 WO2018087132A1 (en) 2016-11-10 2017-11-08 Pharmaceutical composition, methods for treating and uses thereof

Publications (1)

Publication Number Publication Date
MX2019005435A true MX2019005435A (es) 2019-07-10

Family

ID=60293959

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019005435A MX2019005435A (es) 2016-11-10 2017-11-08 Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2023000796A MX2023000796A (es) 2016-11-10 2019-05-09 Composicion farmaceutica, metodos para tratamiento y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023000796A MX2023000796A (es) 2016-11-10 2019-05-09 Composicion farmaceutica, metodos para tratamiento y sus usos.

Country Status (13)

Country Link
US (4) US20180125813A1 (es)
EP (1) EP3538107A1 (es)
JP (2) JP2019533709A (es)
KR (2) KR20190084096A (es)
CN (1) CN109922813A (es)
AU (2) AU2017357589B2 (es)
BR (1) BR112019008384A2 (es)
CA (1) CA3039745A1 (es)
CL (1) CL2019001214A1 (es)
MA (1) MA46742A (es)
MX (2) MX2019005435A (es)
PH (1) PH12019501018A1 (es)
WO (1) WO2018087132A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE041709T2 (hu) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN113181161A (zh) 2013-04-18 2021-07-30 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
CN112557533A (zh) * 2020-11-29 2021-03-26 北京康立生医药技术开发有限公司 一种恩格列净的分析方法
WO2023114170A1 (en) * 2021-12-14 2023-06-22 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors for treating chronic kidney disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52365B (en) 2004-03-16 2012-12-31 Boehringer Ingelheim International Gmbh BENZOL DERIVATIVES SUBSTITUTED BY GLUCOPYRANOSIL, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS, THEIR USE AND THE PROCEDURE FOR THEIR PRODUCTION
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
UY32427A (es) 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
PT2395968T (pt) 2009-02-13 2024-03-05 Boehringer Ingelheim Int Composição farmacêutica compreendendo derivados de glucopiranosil difenilmetano, sua forma de dosagem farmacêutica, processo para a sua preparação e suas utilizações para controlo glicémico melhorado num doente
JP5758900B2 (ja) 2009-09-30 2015-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換ベンジルベンゼン誘導体の調製方法
NZ598318A (en) 2009-09-30 2014-02-28 Boehringer Ingelheim Int Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
CA2812519A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HUE041709T2 (hu) * 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
CN113181161A (zh) * 2013-04-18 2021-07-30 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途

Also Published As

Publication number Publication date
CL2019001214A1 (es) 2019-07-26
CA3039745A1 (en) 2018-05-17
AU2017357589A1 (en) 2019-04-18
AU2017357589B2 (en) 2023-05-11
CN109922813A (zh) 2019-06-21
KR20190084096A (ko) 2019-07-15
US20210228533A1 (en) 2021-07-29
US20180125813A1 (en) 2018-05-10
US20220288012A1 (en) 2022-09-15
PH12019501018A1 (en) 2019-12-16
JP2019533709A (ja) 2019-11-21
MX2023000796A (es) 2023-02-27
WO2018087132A1 (en) 2018-05-17
EP3538107A1 (en) 2019-09-18
AU2023203321A1 (en) 2023-06-22
JP2023010710A (ja) 2023-01-20
US20200138770A1 (en) 2020-05-07
KR20230162125A (ko) 2023-11-28
MA46742A (fr) 2019-09-18
BR112019008384A2 (pt) 2019-07-09

Similar Documents

Publication Publication Date Title
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX370792B (es) Composiciones para usarse en el tratamiento de cáncer.
SG10201902664RA (en) Combination therapy for treating cancer
MX2018015089A (es) Combinacion de linagliptina y metformina.
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
WO2015130554A3 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2020001256A (es) Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos.
WO2017079403A3 (en) Polymeric nanoparticles
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
EA201991119A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
MX2017011838A (es) Composiciones y metodos para tratar carcinoma hepatocelular.
WO2016164719A3 (en) Methods used to treat cancer